Joseph Thome

Laura Chico

Ryan Deschner

Louise Chen

Aydin Huseynov

Christopher Raymond

Dennis Ding

Prakhar Agrawal

Roanna Clarissa Ruiz

Yuchen Ding

Allison Bratzel

Ashleigh Acker

John Kim

Matthew Kaplan

Thomas Yip

Yigal Nochomovitz

- Ardelyx is highly confident in its two main products, projecting **Ibsrela** to reach **$1 billion** in sales and **Exposa** to reach **$750 million**.  **[1437402_tx_379074_0]** **[1437402_tx_379074_2]** 
- The company raised its full-year guidance for **Ibsrela** from **$240 million-$250 million** to **$250 million-$260 million**.  **[1437402_tx_379074_4]** 
- **Exposa** has shown month-over-month prescription growth since February, with positive Q2 signs in new and refill prescriptions, as the company focuses on the **220,000-patient non-Medicare market**.  **[1437402_tx_379074_0]** **[1437402_tx_379074_5]** 
- A hearing for Ardelyx's legal challenge against CMS regarding the TDAPA rule is scheduled for **September 25** in district court.  **[1437402_tx_379074_7]** 
- The company indicates that profitability and breakeven are not far in the distant horizon.  **[1437402_tx_379074_8]**

Ardelyx Provides Updates on Product Momentum, Raised Guidance, and Legal Proceedings

ARDELYX (ARDX)